Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 232 articles:
HTML format



Single Articles


    July 2021
  1. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    PubMed     Abstract available


  2. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    PubMed     Abstract available


    June 2021
  3. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    PubMed     Abstract available


  4. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    PubMed     Abstract available


  5. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    PubMed     Abstract available


    May 2021
  6. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    PubMed     Abstract available


  7. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    PubMed     Abstract available


  8. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    PubMed     Abstract available


    April 2021
  9. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    PubMed    


  10. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    PubMed     Abstract available


  11. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    PubMed     Abstract available


  12. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    PubMed     Abstract available


    March 2021
  13. LAZAREVIC M, Djedovic N, Stanisavljevic S, Dimitrijevic M, et al
    Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies.
    J Neuroimmunol. 2021;354:577547.
    PubMed     Abstract available


  14. GIARRAPUTO J, Giamberardino S, Arvai S, Maichle S, et al
    Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    J Neuroimmunol. 2021;354:577541.
    PubMed     Abstract available


    February 2021
  15. XIANG W, Xie C, Guan Y
    The identification, development and therapeutic potential of IL-10-producing regulatory B cells in multiple sclerosis.
    J Neuroimmunol. 2021;354:577520.
    PubMed     Abstract available


  16. LUCCHINI M, Giuffre GM, Nociti V, Bianco A, et al
    Defining the disease course of TNFalpha blockers-associated Multiple Sclerosis.
    J Neuroimmunol. 2021;353:577525.
    PubMed     Abstract available


  17. UCHIDA N, Mori K, Fujita-Nakata M, Nakanishi M, et al
    Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.
    J Neuroimmunol. 2021;353:577500.
    PubMed     Abstract available


  18. LI Q, Liu Y, Zeng Y
    Questions about data: Importance of serum amyloid A level in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577516.
    PubMed    


    January 2021
  19. KHADEMI B, Khorrami M, Ayromlou H, Rikhtegar R, et al
    An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577507.
    PubMed     Abstract available


  20. MIMPEN M, Rolf L, Muris AH, Gerlach O, et al
    NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.
    J Neuroimmunol. 2021;353:577499.
    PubMed     Abstract available


  21. ONMAZ DE, Isik SMT, Abusoglu S, Ekmekci AH, et al
    Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis.
    J Neuroimmunol. 2021;353:577497.
    PubMed     Abstract available


  22. NIU Y, Li Y
    The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.
    J Neuroimmunol. 2021;352:577465.
    PubMed    


  23. ZILIOTTO N, Lamberti N, Manfredini F, Straudi S, et al
    Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.
    J Neuroimmunol. 2021;352:577473.
    PubMed     Abstract available


    December 2020
  24. STASCHEIT F, Li L, Mai K, Baum K, et al
    Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases.
    J Neuroimmunol. 2020;351:577469.
    PubMed     Abstract available


  25. YOKOTE H, Toru S, Nishida Y, Hattori T, et al
    Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis.
    J Neuroimmunol. 2020;351:577466.
    PubMed     Abstract available


  26. GARCIA-FERNANDEZ FJ, Garcia-Fernandez AE, Nava E, Del Pozo JSG, et al
    A bibliometric evaluation of the top 100 cited natalizumab articles.
    J Neuroimmunol. 2020;349:577379.
    PubMed     Abstract available


    November 2020
  27. BILGE N, Simsek F, Yevgi R, Ceylan M, et al
    Low serum Alpha-SYNUCLEIN and oligomer Alpha-SYNUCLEIN levels in multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577432.
    PubMed     Abstract available


  28. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2020;350:577433.
    PubMed     Abstract available


  29. GONCALVES MVM, Brandao WN, Longo C, Peron JPS, et al
    Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
    J Neuroimmunol. 2020;350:577435.
    PubMed     Abstract available


    October 2020
  30. MARTINEZ-LARROSA J, Matute-Blanch C, Montalban X, Comabella M, et al
    Modelling multiple sclerosis using induced pluripotent stem cells.
    J Neuroimmunol. 2020;349:577425.
    PubMed     Abstract available


    September 2020
  31. NEKRASOVA I, Shirshev S
    Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
    J Neuroimmunol. 2020;349:577421.
    PubMed     Abstract available


  32. HAWKE S, Zinger A, Juillard PG, Holdaway K, et al
    Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    J Neuroimmunol. 2020;349:577392.
    PubMed     Abstract available


  33. SIGNORIELLO E, Iardino P, Casertano S, De Lucia D, et al
    12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
    J Neuroimmunol. 2020;348:577385.
    PubMed     Abstract available


    August 2020
  34. ISMAIL S, Engin K, Ozan K, Mustafa C, et al
    Analysis of plasma protein biomarkers in childhood onset multiple sclerosis.
    J Neuroimmunol. 2020;348:577359.
    PubMed     Abstract available


  35. TRENOVA AG, Miteva LD, Stanilova SA
    Association between TNFA, IL10 and IL18 promoter gene variants and cognitive functions in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2020;347:577357.
    PubMed     Abstract available


  36. SOTIROPOULOS MG, Chitnis T
    Opposing and potentially antagonistic effects of BMP and TGF-beta in multiple sclerosis: The "Yin and Yang" of neuro-immune Signaling.
    J Neuroimmunol. 2020;347:577358.
    PubMed     Abstract available


  37. IBRAHIM SH, El-Mehdawy KM, Seleem M, El-Sawalhi MM, et al
    Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
    J Neuroimmunol. 2020;347:577356.
    PubMed     Abstract available


  38. SALAVISA M, Paixao P, Ladeira AF, Mendes A, et al
    Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse.
    J Neuroimmunol. 2020;347:577355.
    PubMed     Abstract available


    July 2020
  39. ACAR NP, Tuncer A, Ozkazanc D, Ozbay FG, et al
    An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta1 and fingolimod therapy.
    J Neuroimmunol. 2020;347:577353.
    PubMed     Abstract available


  40. GHADERIAN S, Shomali N, Behravesh S, Danbaran GR, et al
    The emerging role of lncRNAs in multiple sclerosis.
    J Neuroimmunol. 2020;347:577347.
    PubMed     Abstract available


  41. STEFANOVIC M, Zivotic I, Stojkovic L, Dincic E, et al
    The association of genetic variants IL2RA rs2104286, IFI30 rs11554159 and IKZF3 rs12946510 with multiple sclerosis onset and severity in patients from Serbia.
    J Neuroimmunol. 2020;347:577346.
    PubMed     Abstract available


  42. CIARDI MR, Zingaropoli MA, Pasculli P, Perri V, et al
    The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.
    J Neuroimmunol. 2020;346:577323.
    PubMed     Abstract available


  43. KENNEDY PGE, Graner MW, Walker D, Pointon T, et al
    Recombinant antibodies derived from laser captured single plasma cells of multiple sclerosis brain identified phage peptides which may be used as tools for characterizing intrathecal IgG response.
    J Neuroimmunol. 2020;347:577319.
    PubMed     Abstract available


  44. TIAN X, Chen C, Ma L, Wei R, et al
    Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2020;347:577317.
    PubMed     Abstract available


  45. HOUEN G, Heiden J, Trier NH, Draborg AH, et al
    Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis.
    J Neuroimmunol. 2020;346:577314.
    PubMed     Abstract available


  46. KEYVANI H, Zahednasab H, Aljanabi HAA, Asadi M, et al
    The role of human herpesvirus-6 and inflammatory markers in the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2020;346:577313.
    PubMed     Abstract available


    June 2020
  47. YETKIN MF, Mirza M
    Neutrophil to-lymphocyte ratio as a possible predictor of prognosis in recently diagnosed multiple sclerosis patients.
    J Neuroimmunol. 2020;346:577307.
    PubMed    


  48. AL-NASERI MAS, Salman ED, Ad'hiah AH
    Relapsing-remitting multiple sclerosis: A profile of interleukine-1 gene cluster polymorphisms in Iraqi patients.
    J Neuroimmunol. 2020;346:577291.
    PubMed     Abstract available


  49. NAJJAR E, Staun-Ram E, Volkowich A, Miller A, et al
    Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    J Neuroimmunol. 2020;343:577230.
    PubMed     Abstract available


  50. AHARONI R, Eilam R, Schottlender N, Radomir L, et al
    Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis.
    J Neuroimmunol. 2020;345:577281.
    PubMed     Abstract available


    May 2020
  51. RACKE MK, Newsome SD
    Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration.
    J Neuroimmunol. 2020 May 31:577283. doi: 10.1016/j.jneuroim.2020.577283.
    PubMed    


  52. CHIARINI M, Paghera S, Moratto D, Rossi N, et al
    Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
    J Neuroimmunol. 2020;345:577282.
    PubMed     Abstract available


    April 2020
  53. BOULLERNE AI, Adami GR, Schwartz JL, Skias D, et al
    Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity.
    J Neuroimmunol. 2020;343:577237.
    PubMed     Abstract available


    March 2020
  54. TAHMASEBIVAND M, Mousavi SR, Khorrami M, Ayromlou H, et al
    miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta.
    J Neuroimmunol. 2020;342:577212.
    PubMed     Abstract available


    February 2020
  55. LISAK RP, Nedelkoska L, Benjamins JA
    Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis.
    J Neuroimmunol. 2020;342:577188.
    PubMed     Abstract available


  56. NYSTAD AE, Lereim RR, Wergeland S, Oveland E, et al
    Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
    J Neuroimmunol. 2020;339:577091.
    PubMed     Abstract available


  57. HABIB R, Ocklenburg S, Hoffjan S, Haghikia A, et al
    Association between shorter leukocyte telomeres and multiple sclerosis.
    J Neuroimmunol. 2020;341:577187.
    PubMed     Abstract available


    January 2020
  58. SHAHIDI SH, Kordi MR, Rajabi H, Malm C, et al
    Exercise modulates the levels of growth inhibitor genes before and after multiple sclerosis.
    J Neuroimmunol. 2020;341:577172.
    PubMed     Abstract available


  59. HEMING M, Lohmann L, Schulte-Mecklenbeck A, Brix T, et al
    Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis.
    J Neuroimmunol. 2020;341:577171.
    PubMed     Abstract available


  60. SAHAMI-FARD MH, Mozhdeh M, Izadpanah F, Kashani HH, et al
    Interleukin 7 receptor T244I polymorphism and the multiple sclerosis susceptibility: a meta-analysis.
    J Neuroimmunol. 2020;341:577166.
    PubMed     Abstract available


  61. PANDYA D, Hellerslia V, Gettings E
    Acquired factor VIII inhibitor in a patient with multiple sclerosis treated with interferon beta-1a.
    J Neuroimmunol. 2020;340:577146.
    PubMed     Abstract available


  62. HAKANSSON I, Ernerudh J, Vrethem M, Dahle C, et al
    Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2020;340:577147.
    PubMed     Abstract available


    December 2019
  63. CAVALLA P, Caropreso P, Limoncelli S, Bosa C, et al
    Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders.
    J Neuroimmunol. 2019;339:577122.
    PubMed     Abstract available


    November 2019
  64. MONTEIRO A, Rosado P, Rosado L, Fonseca AM, et al
    Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    J Neuroimmunol. 2019;339:577113.
    PubMed     Abstract available


  65. MARCUCCI SB, Obeidat AZ
    EBNA1, EBNA2, and EBNA3 link Epstein-Barr virus and hypovitaminosis D in multiple sclerosis pathogenesis.
    J Neuroimmunol. 2019;339:577116.
    PubMed     Abstract available


  66. AMMITZBOLL C, von Essen MR, Chow HH, McWilliam O, et al
    MAIT cell subtypes in multiple sclerosis.
    J Neuroimmunol. 2019;339:577117.
    PubMed     Abstract available


  67. SPANIER JA, Nashold FE, Nelson CD, Praska CE, et al
    Vitamin D3-mediated resistance to a multiple sclerosis model disease depends on myeloid cell 1,25-dihydroxyvitamin D3 synthesis and correlates with increased CD4(+) T cell CTLA-4 expression.
    J Neuroimmunol. 2019;338:577105.
    PubMed     Abstract available


  68. NASI M, Bianchini E, De Biasi S, Gibellini L, et al
    Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2019;338:577107.
    PubMed     Abstract available


  69. GAETANI L, Di Carlo M, Brachelente G, Valletta F, et al
    Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis.
    J Neuroimmunol. 2019;339:577108.
    PubMed     Abstract available


  70. ARRU G, Sechi E, Mariotto S, Zarbo IR, et al
    Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD.
    J Neuroimmunol. 2019;338:577110.
    PubMed     Abstract available


    October 2019
  71. CAO Q, Zheng C, Xie Z, Liu L, et al
    The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3.
    J Neuroimmunol. 2019;338:577079.
    PubMed     Abstract available


  72. KOLIC I, Stojkovic L, Dincic E, Jovanovic I, et al
    Expression of LEP, LEPR and PGC1A genes is altered in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;338:577090.
    PubMed     Abstract available


  73. BASNYAT P, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis.
    J Neuroimmunol. 2019;335:577020.
    PubMed     Abstract available


  74. PETERSEN ER, Ammitzboll C, Sondergaard HB, Oturai AB, et al
    Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis.
    J Neuroimmunol. 2019;337:577085.
    PubMed     Abstract available


    September 2019
  75. RANJBAR R, Karampoor S, Jalilian FA
    The protective effect of Helicobacter Pylori infection on the susceptibility of multiple sclerosis.
    J Neuroimmunol. 2019;337:577069.
    PubMed     Abstract available


  76. KURTUNCU M, Yilmaz V, Akcay HI, Turkoglu R, et al
    Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2019;337:577065.
    PubMed     Abstract available


  77. ABDEL-DAYEM MA, Shaker ME, Gameil NM
    Impact of interferon beta-1b, interferon beta-1a and fingolimod therapies on serum interleukins-22, 32alpha and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577062.
    PubMed     Abstract available


  78. AFSHAR B, Khalifehzadeh-Esfahani Z, Seyfizadeh N, Rezaei Danbaran G, et al
    The role of immune regulatory molecules in multiple sclerosis.
    J Neuroimmunol. 2019;337:577061.
    PubMed     Abstract available


    August 2019
  79. LIANG H, Gao W, Liu X, Liu J, et al
    The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population.
    J Neuroimmunol. 2019;337:577045.
    PubMed     Abstract available


  80. ZAROBKIEWICZ MK, Kowalska W, Halczuk P, Wos J, et al
    RORgammaT is overexpressed in iNKT and gammadelta T cells during relapse in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577046.
    PubMed     Abstract available


  81. DURCAN R, Heffron C, Sweeney B
    Natalizumab induced cutaneous sarcoidosis-like reaction.
    J Neuroimmunol. 2019;333:476955.
    PubMed     Abstract available


    June 2019
  82. IMITOLA J
    Regenerative neuroimmunology: The impact of immune and neural stem cell interactions for translation in neurodegeneration and repair.
    J Neuroimmunol. 2019;331:1-3.
    PubMed    


  83. ANTEL JP, Lin YH, Cui QL, Pernin F, et al
    Immunology of oligodendrocyte precursor cells in vivo and in vitro.
    J Neuroimmunol. 2019;331:28-35.
    PubMed     Abstract available


  84. ZORLU N, Hoffjan S, Haghikia A, Deyneko IV, et al
    Evaluation of variation in genes of the arylhydrocarbon receptor pathway for an association with multiple sclerosis.
    J Neuroimmunol. 2019;334:576979.
    PubMed     Abstract available


    May 2019
  85. KOCH MW, Liu WQ, Camara-Lemarroy C, Zhang Y, et al
    Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.
    J Neuroimmunol. 2019;334:576974.
    PubMed     Abstract available


  86. ZURAWSKA A, Mycko MP, Selmaj KW
    Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis.
    J Neuroimmunol. 2019;334:576971.
    PubMed     Abstract available


  87. RASOOLI TEHRANI A, Gholipour S, Sharifi R, Yadegari S, et al
    Plasma levels of CTRP-3, CTRP-9 and apelin in women with multiple sclerosis.
    J Neuroimmunol. 2019;333:576968.
    PubMed     Abstract available


  88. TOMESCU-BACIU A, Johansen JN, Holmoy T, Greiff V, et al
    Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis.
    J Neuroimmunol. 2019;333:576966.
    PubMed     Abstract available


  89. LOVETT-RACKE AE, Gormley M, Liu Y, Yang Y, et al
    B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
    J Neuroimmunol. 2019;332:187-197.
    PubMed     Abstract available


    April 2019
  90. SETIADI AF, Abbas AR, Jeet S, Wong K, et al
    IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;332:147-154.
    PubMed     Abstract available


    March 2019
  91. VOO VTF, O'Brien T, Butzkueven H, Monif M, et al
    The role of vitamin D and P2X7R in multiple sclerosis.
    J Neuroimmunol. 2019;330:159-169.
    PubMed     Abstract available


  92. CIERNY D, Michalik J, Dubovan P, Skerenova M, et al
    The association of rs703842 variants in CYP27B1 with multiple sclerosis susceptibility is influenced by the HLA-DRB1*15:01 allele in Slovaks.
    J Neuroimmunol. 2019;330:123-129.
    PubMed     Abstract available


  93. ANNUNZIATA P, Masi G, Cioni C
    Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients.
    J Neuroimmunol. 2019;330:130-135.
    PubMed     Abstract available


  94. AMMITZBOLL C, Bornsen L, Petersen ER, Oturai AB, et al
    Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.
    J Neuroimmunol. 2019;330:90-95.
    PubMed     Abstract available


    February 2019
  95. DA SILVA BERNARDES M, Antao Paiva CL, Ribeiro Paradela E, Papais Alvarenga M, et al
    Familial multiple sclerosis in a Brazilian sample: Is HLA-DR15 involved in susceptibility to the disease?
    J Neuroimmunol. 2019;330:74-80.
    PubMed     Abstract available


  96. ZAROBKIEWICZ MK, Kowalska W, Rolinski J, Bojarska-Junak AA, et al
    gammadelta T lymphocytes in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2019;330:67-73.
    PubMed     Abstract available


  97. AL-TEMAIMI R, Cherian P, Abu-Farha M, Alroughani R, et al
    Angiopoietin-like proteins in multiple sclerosis.
    J Neuroimmunol. 2019;330:31-34.
    PubMed     Abstract available


    January 2019
  98. MAUSNER-FAINBERG K, Penn M, Golan M, Benhamou M, et al
    Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30476.
    PubMed     Abstract available


  99. DOLATI S, Babaloo Z, Ayromlou H, Ahmadi M, et al
    Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis.
    J Neuroimmunol. 2019 Jan 17. pii: S0165-5728(18)30466.
    PubMed     Abstract available


    December 2018
  100. EMAMI ALEAGHA MS, Siroos B, Allameh A, Shakiba S, et al
    Calcitriol, but not FGF23, increases in CSF and serum of MS patients.
    J Neuroimmunol. 2018;328:89-93.
    PubMed     Abstract available


  101. ARAMIDEH KHOUY R, Karampoor S, Keyvani H, Bokharaei-Salim F, et al
    The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    J Neuroimmunol. 2018;328:94-97.
    PubMed     Abstract available


  102. MEHTA D, Wani S, Wallace L, Henders AK, et al
    Cumulative influence of parity-related genomic changes in multiple sclerosis.
    J Neuroimmunol. 2018;328:38-49.
    PubMed     Abstract available


  103. YOUSEFI F, Lavi Arab F, Saeidi K, Amiri H, et al
    Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection.
    J Neuroimmunol. 2018;328:20-34.
    PubMed     Abstract available


    November 2018
  104. MASOUMI F, Ghorbani S, Talebi F, Branton WG, et al
    Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;328:50-59.
    PubMed     Abstract available


  105. MONTEIRO A, Cruto C, Rosado P, Rosado L, et al
    Interferon-beta treated-multiple sclerosis patients exhibit a decreased ratio between immature/transitional B cell subset and plasmablasts.
    J Neuroimmunol. 2018;326:49-54.
    PubMed     Abstract available


  106. ANNIBALI V, Umeton R, Palermo A, Severa M, et al
    Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients.
    J Neuroimmunol. 2018;324:165-171.
    PubMed     Abstract available


  107. LOTAN I, Hellmann MA, Benninger F, Stiebel-Kalish H, et al
    Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.
    J Neuroimmunol. 2018;324:115-118.
    PubMed     Abstract available


  108. ROCHA NP, Colpo GD, Bravo-Alegria J, Lincoln JA, et al
    Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis.
    J Neuroimmunol. 2018;326:45-48.
    PubMed     Abstract available


  109. JENSEN PEH, Warnke C, Ingenhoven K, Piccoli L, et al
    Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
    J Neuroimmunol. 2018;326:19-27.
    PubMed     Abstract available


    October 2018
  110. SAFIZADEH B, Hoshyar R, Mehrpour M, Eftekhar M, et al
    The role of expression and activity of 15-Lipoxygenase isoforms and related cytokines in patients with Multiple Sclerosis and healthy controls.
    J Neuroimmunol. 2018;325:32-42.
    PubMed     Abstract available


  111. KVISTAD SS, Myhr KM, Holmoy T, Benth JS, et al
    Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.
    J Neuroimmunol. 2018;323:73-77.
    PubMed     Abstract available


  112. SLAVIN YN, Bo M, Caggiu E, Sechi G, et al
    High levels of antibodies against PtpA and PknG secreted by Mycobacterium avium ssp. paratuberculosis are present in neuromyelitis optica spectrum disorder and multiple sclerosis patients.
    J Neuroimmunol. 2018;323:49-52.
    PubMed     Abstract available


  113. AMORUSO A, Blonda M, D'Arrigo G, Grasso R, et al
    Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients.
    J Neuroimmunol. 2018;323:43-48.
    PubMed     Abstract available


  114. HAARMANN A, Hahnel L, Schuhmann MK, Buttmann M, et al
    Age-adjusted CSF beta2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity.
    J Neuroimmunol. 2018;323:19-27.
    PubMed     Abstract available


  115. KOSTIC M, Zivkovic N, Cvetanovic A, Stojanovic I, et al
    Granulocyte-macrophage colony-stimulating factor as a mediator of autoimmunity in multiple sclerosis.
    J Neuroimmunol. 2018;323:1-9.
    PubMed     Abstract available


  116. MOHAMMADZADEH A, Rad IA, Ahmadi-Salmasi B
    CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.
    J Neuroimmunol. 2018;323:105-108.
    PubMed     Abstract available


  117. ALROUJI M, Manouchehrinia A, Gran B, Constantinescu CS, et al
    Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis.
    J Neuroimmunol. 2018 Oct 9. pii: S0165-5728(18)30130.
    PubMed     Abstract available


  118. TAVAKOLPOUR V, Shokri G, Naser Moghadasi A, Mozafari Nahavandi P, et al
    Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity.
    J Neuroimmunol. 2018 Oct 4. pii: S0165-5728(18)30173.
    PubMed     Abstract available


    September 2018
  119. JAFARZADEH A, Nemati M
    Therapeutic potentials of ginger for treatment of Multiple sclerosis: A review with emphasis on its immunomodulatory, anti-inflammatory and anti-oxidative properties.
    J Neuroimmunol. 2018;324:54-75.
    PubMed     Abstract available


  120. MCWILLIAM O, Sellebjerg F, Marquart HV, von Essen MR, et al
    B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTalpha and TGFbeta1 response.
    J Neuroimmunol. 2018 Sep 7. pii: S0165-5728(18)30276.
    PubMed     Abstract available


    August 2018
  121. SALAPA HE, Johnson C, Hutchinson C, Popescu BF, et al
    Dysfunctional RNA binding proteins and stress granules in multiple sclerosis.
    J Neuroimmunol. 2018 Aug 29. pii: S0165-5728(18)30377.
    PubMed     Abstract available


  122. FENOGLIO C, Oldoni E, Serpente M, De Riz MA, et al
    LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients.
    J Neuroimmunol. 2018 Aug 27. pii: S0165-5728(18)30259.
    PubMed     Abstract available


  123. FEKI S, Gargouri S, Mejdoub S, Dammak M, et al
    The intrathecal polyspecific antiviral immune response (MRZ reaction): A potential cerebrospinal fluid marker for multiple sclerosis diagnosis.
    J Neuroimmunol. 2018;321:66-71.
    PubMed     Abstract available


  124. LAI W, Kinoshita M, Peng A, Li W, et al
    Does pregnancy affect women with multiple sclerosis? A prospective study in Western China.
    J Neuroimmunol. 2018;321:24-28.
    PubMed     Abstract available


  125. MOHAJER B, Abbasi N, Pishgar F, Abdolalizadeh A, et al
    HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis.
    J Neuroimmunol. 2018;321:117-124.
    PubMed     Abstract available


    July 2018
  126. MIYAKE S, Yamamura T
    Gut environmental factors and multiple sclerosis.
    J Neuroimmunol. 2018 Jul 27. pii: S0165-5728(17)30414.
    PubMed     Abstract available


  127. KARAMPOOR S, Zahednasab H, Etemadifar M, Keyvani H, et al
    The levels of soluble forms of CD21 and CD83 in multiple sclerosis.
    J Neuroimmunol. 2018;320:11-14.
    PubMed     Abstract available


    June 2018
  128. HAASE S, Wilck N, Kleinewietfeld M, Muller DN, et al
    Sodium chloride triggers Th17 mediated autoimmunity.
    J Neuroimmunol. 2018 Jun 30. pii: S0165-5728(17)30512.
    PubMed     Abstract available


  129. SABERI R, Sharif M, Sarvi S, Aghayan SA, et al
    Is Toxoplasma gondii playing a positive role in multiple sclerosis risk? A systematic review and meta-analysis.
    J Neuroimmunol. 2018 Jun 22. pii: S0165-5728(17)30579.
    PubMed     Abstract available


  130. SERAFINI B, Zandee S, Rosicarelli B, Scorsi E, et al
    Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
    J Neuroimmunol. 2018;319:9-12.
    PubMed    


  131. AKAISHI T, Takahashi T, Nakashima I
    Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis.
    J Neuroimmunol. 2018;319:37-40.
    PubMed     Abstract available


  132. FAGONE P, Mazzon E, Cavalli E, Bramanti A, et al
    Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences.
    J Neuroimmunol. 2018 Jun 15. pii: S0165-5728(18)30141.
    PubMed     Abstract available


    May 2018
  133. DUPREE JL, Feinstein DL
    Influence of diet on axonal damage in the EAE mouse model of multiple sclerosis.
    J Neuroimmunol. 2018 May 20. pii: S0165-5728(18)30104.
    PubMed     Abstract available


  134. BREUER J, Loser K, Mykicki N, Wiendl H, et al
    Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?
    J Neuroimmunol. 2018 May 18. pii: S0165-5728(17)30478.
    PubMed     Abstract available


  135. CHU F, Shi M, Zheng C, Shen D, et al
    The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2018;318:1-7.
    PubMed     Abstract available


    April 2018
  136. CASTANEDA-MORENO VA, De la Cruz-Mosso U, Torres-Carrillo N, Macias-Islas MA, et al
    MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.
    J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593.
    PubMed     Abstract available


  137. YAN J, Winterford CM, Catts VS, Pat BK, et al
    Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis.
    J Neuroimmunol. 2018 Apr 6. pii: S0165-5728(17)30536.
    PubMed     Abstract available


    March 2018
  138. PAUNOVIC V, Petrovic IV, Milenkovic M, Janjetovic K, et al
    Autophagy-independent increase of ATG5 expression in T cells of multiple sclerosis patients.
    J Neuroimmunol. 2018 Mar 5. pii: S0165-5728(17)30538.
    PubMed     Abstract available


  139. SMITH PA, Schmid C, Zurbruegg S, Jivkov M, et al
    Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    J Neuroimmunol. 2018 Mar 3. pii: S0165-5728(17)30519.
    PubMed     Abstract available


  140. ASHTARI F, Esmaeil N, Mansourian M, Poursafa P, et al
    An 8-year study of people with multiple sclerosis in Isfahan, Iran: Association between environmental air pollutants and severity of disease.
    J Neuroimmunol. 2018 Mar 2. pii: S0165-5728(18)30019.
    PubMed     Abstract available


    February 2018
  141. MONTEIRO A, Cruto C, Rosado P, Martinho A, et al
    Characterization of circulating gamma-delta T cells in relapsing vs remission multiple sclerosis.
    J Neuroimmunol. 2018 Feb 24. pii: S0165-5728(17)30533.
    PubMed     Abstract available


  142. GEORGE JD, Kim E, Spain R, Bourdette D, et al
    Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis.
    J Neuroimmunol. 2018;315:24-27.
    PubMed     Abstract available


  143. IP PP, Chung CY, Chang CC, Lee YF, et al
    Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets.
    J Neuroimmunol. 2018 Feb 8. pii: S0165-5728(17)30498.
    PubMed     Abstract available


    January 2018
  144. LIU C, Liu H, Jin H, Yue X, et al
    Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.
    J Neuroimmunol. 2018 Jan 31. pii: S0165-5728(17)30560.
    PubMed     Abstract available


  145. BAULINA N, Kulakova O, Kiselev I, Osmak G, et al
    Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission.
    J Neuroimmunol. 2018 Jan 5. pii: S0165-5728(17)30447.
    PubMed     Abstract available


  146. OZKUL C, Guclu-Gunduz A, Irkec C, Fidan I, et al
    Effect of combined exercise training on serum brain-derived neurotrophic factor, suppressors of cytokine signaling 1 and 3 in patients with multiple sclerosis.
    J Neuroimmunol. 2018 Jan 3. pii: S0165-5728(17)30484.
    PubMed     Abstract available


    December 2017
  147. IMITOLA J, Rasouli J, Watanabe F, Mahajan K, et al
    Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions.
    J Neuroimmunol. 2017 Dec 22. pii: S0165-5728(17)30304.
    PubMed     Abstract available


  148. ROLLA S, De Mercanti SF, Bardina V, Horakova D, et al
    Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses.
    J Neuroimmunol. 2017;313:89-91.
    PubMed     Abstract available


  149. LI R, Sun X, Shu Y, Wang Y, et al
    Serum CCL20 and its association with SIRT1 activity in multiple sclerosis patients.
    J Neuroimmunol. 2017;313:56-60.
    PubMed     Abstract available


  150. GILLI F, Royce DB, DiSano KD, Pachner AR, et al
    Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;313:34-40.
    PubMed     Abstract available


  151. AKAISHI T, Kaneko K, Himori N, Takeshita T, et al
    Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2017;313:10-15.
    PubMed     Abstract available


  152. BANSI J, Koliamitra C, Bloch W, Joisten N, et al
    Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training.
    J Neuroimmunol. 2017 Dec 6. pii: S0165-5728(17)30420.
    PubMed     Abstract available


    November 2017
  153. KIM MJ, Lim JY, Park SA, Park SI, et al
    Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis.
    J Neuroimmunol. 2017 Nov 29. pii: S0165-5728(17)30134.
    PubMed     Abstract available


  154. MONTELEONE F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, et al
    Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain.
    J Neuroimmunol. 2017 Nov 20. pii: S0165-5728(17)30179.
    PubMed     Abstract available


  155. ROLF L, Muris AH, Theunissen R, Hupperts R, et al
    Vitamin D3 supplementation and the IL-2/IL-2R pathway in multiple sclerosis: Attenuation of progressive disturbances?
    J Neuroimmunol. 2017 Nov 10. pii: S0165-5728(17)30208.
    PubMed     Abstract available


  156. MAZDEH M, Moradi N, Khoshroo E, Shayesteh Z, et al
    Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    J Neuroimmunol. 2017 Nov 8. pii: S0165-5728(17)30405.
    PubMed     Abstract available


    September 2017
  157. MERKER M, Eichler S, Herrmann AM, Wiendl H, et al
    Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 21. pii: S1521-6616(17)30639.
    PubMed     Abstract available


  158. BADIHIAN S, Manouchehri N, Badihian N
    More evidence is needed to show any role of cytomegalovisrus and varicella zoster virus in pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2017 Sep 18. pii: S0165-5728(17)30401.
    PubMed    


  159. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Abstract available


  160. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Abstract available


  161. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Abstract available


  162. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Abstract available


  163. LINDSEY JW
    Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins.
    J Neuroimmunol. 2017;310:131-134.
    PubMed     Abstract available


  164. ALVARENGA MP, Fernandez O, Leyva L, Campanella L, et al
    The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro.
    J Neuroimmunol. 2017;310:1-7.
    PubMed     Abstract available


  165. VERCELLINO M, Trebini C, Capello E, Mancardi GL, et al
    Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.
    J Neuroimmunol. 2017 Sep 8. pii: S0165-5728(17)30131.
    PubMed     Abstract available


    August 2017
  166. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Abstract available


  167. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Abstract available


  168. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Abstract available


  169. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Abstract available


  170. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Abstract available


  171. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Abstract available


  172. HENDRICKX DAE, van Eden CG, Schuurman KG, Hamann J, et al
    Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology.
    J Neuroimmunol. 2017;309:12-22.
    PubMed     Abstract available


  173. WILDNER P, Selmaj KW
    Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
    J Neuroimmunol. 2017 Aug 2. pii: S0165-5728(17)30263.
    PubMed     Abstract available


    July 2017
  174. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Abstract available


    June 2017
  175. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Abstract available


  176. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Abstract available


  177. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Abstract available


  178. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Abstract available


  179. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Abstract available


  180. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Abstract available


    May 2017
  181. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Abstract available


  182. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Abstract available


  183. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Abstract available


  184. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Abstract available


  185. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Abstract available


    April 2017
  186. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Abstract available


  187. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Abstract available


  188. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Abstract available


  189. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Abstract available


  190. AGLIARDI C, Guerini FR, Zanzottera M, Bolognesi E, et al
    Vitamin D-binding protein gene polymorphisms are not associated with MS risk in an Italian cohort.
    J Neuroimmunol. 2017;305:92-95.
    PubMed     Abstract available


  191. SCOTT TF
    Understanding the impact of relapses in the overall course of MS; refinement of the 2 stage natural history model.
    J Neuroimmunol. 2017;305:162-166.
    PubMed     Abstract available


  192. PAWLAK-ADAMSKA E, Nowak O, Karabon L, Pokryszko-Dragan A, et al
    PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS.
    J Neuroimmunol. 2017;305:115-127.
    PubMed     Abstract available


  193. KIMURA A, Takemura M, Saito K, Serrero G, et al
    Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:175-181.
    PubMed     Abstract available


    March 2017
  194. MINDUR JE, Valenzuela RM, Yadav SK, Boppana S, et al
    IL-27: a potential biomarker for responders to glatiramer acetate therapy.
    J Neuroimmunol. 2017;304:21-28.
    PubMed     Abstract available


    February 2017
  195. PANT AB, Wang Y, Mielcarz DW, Kasper EJ, et al
    Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    J Neuroimmunol. 2017;303:22-30.
    PubMed     Abstract available


  196. DEPAULA-SILVA AB, Hanak TJ, Libbey JE, Fujinami RS, et al
    Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.
    J Neuroimmunol. 2017 Feb 12. pii: S0165-5728(16)30480.
    PubMed     Abstract available


    December 2016
  197. ALVARENGA-FILHO H, Salles M, Hygino J, Ferreira TB, et al
    Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients.
    J Neuroimmunol. 2016 Dec 30. pii: S0165-5728(16)30393.
    PubMed     Abstract available


  198. ANNUNZIATA P, Cioni C, Mugnaini C, Corelli F, et al
    Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
    J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274.
    PubMed     Abstract available


  199. PAOLICELLI D, Manni A, D'Onghia M, Direnzo V, et al
    Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    J Neuroimmunol. 2016 Dec 21. pii: S0165-5728(16)30371.
    PubMed     Abstract available


  200. MATUTE-BLANCH C, Rio J, Villar LM, Midaglia L, et al
    Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 18. pii: S0165-5728(16)30310.
    PubMed     Abstract available


  201. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Abstract available


  202. GORDON-LIPKIN E, Calabresi PA
    Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 14. pii: S0165-5728(16)30447.
    PubMed     Abstract available


  203. HOSSAIN MJ, Tanasescu R, Gran B
    Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.
    J Neuroimmunol. 2016 Dec 13. pii: S0165-5728(16)30448.
    PubMed     Abstract available


    November 2016
  204. HAGHMORAD D, Mahmoudi MB, Salehipour Z, Jalayer Z, et al
    Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 26. pii: S0165-5728(16)30423.
    PubMed     Abstract available


  205. PROKOPOVA B, Hlavacova N, Vlcek M, Penesova A, et al
    Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis.
    J Neuroimmunol. 2016 Nov 19. pii: S0165-5728(16)30241.
    PubMed     Abstract available


  206. ACHIRON A, Zilkha-Falb R, Mashiach R, Gurevich M, et al
    RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30209.
    PubMed     Abstract available


  207. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Angiogenic factors are associated with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30304.
    PubMed     Abstract available


  208. ZHANG Y, Liu G, Duan Y, Han X, et al
    Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China.
    J Neuroimmunol. 2016 Nov 16. pii: S0165-5728(16)30187.
    PubMed     Abstract available


  209. MURIS AH, Smolders J, Rolf L, Thewissen M, et al
    Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study.
    J Neuroimmunol. 2016;300:47-56.
    PubMed     Abstract available


  210. DIAS-CARNEIRO RP, von Glehn F, Moraes AS, Boldrini VO, et al
    MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.
    J Neuroimmunol. 2016;300:30-35.
    PubMed     Abstract available


  211. KALINOWSKA-LYSZCZARZ A, Michalak S, Pawlak MA, Losy J, et al
    Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis.
    J Neuroimmunol. 2016;300:11-14.
    PubMed     Abstract available


  212. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Abstract available


  213. HAAS J, Schwarz A, Korporal-Kuhnke M, Jarius S, et al
    Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 2. pii: S0165-5728(16)30258.
    PubMed     Abstract available


  214. AHARONI R, Rosen C, Shezen E, Bar-Lev DD, et al
    Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 1. pii: S0165-5728(16)30381.
    PubMed     Abstract available


    October 2016
  215. MELIEF J, Koper JW, Endert E, Moller HJ, et al
    Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
    J Neuroimmunol. 2016;299:84-89.
    PubMed     Abstract available


  216. FENOGLIO C, De Riz M, Pietroboni AM, Calvi A, et al
    Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    J Neuroimmunol. 2016;299:81-83.
    PubMed     Abstract available


  217. DA COSTA DS, Hygino J, Ferreira TB, Kasahara TM, et al
    Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:8-18.
    PubMed     Abstract available


  218. BRIKEN S, Rosenkranz SC, Keminer O, Patra S, et al
    Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2016;299:53-58.
    PubMed     Abstract available


  219. JONS D, Kneider M, Fogelstrand L, Jeppsson A, et al
    Early hematopoiesis in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:158-163.
    PubMed     Abstract available


  220. DOOLEY MM, de Gannes SL, Fu KA, Lindsey JW, et al
    The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
    J Neuroimmunol. 2016;299:147-151.
    PubMed     Abstract available


  221. WALLER R, Woodroofe MN, Wharton SB, Ince PG, et al
    Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
    J Neuroimmunol. 2016;299:139-146.
    PubMed     Abstract available


  222. MANE-MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    J Neuroimmunol. 2016;299:112-117.
    PubMed     Abstract available


  223. CROSS AH, Song SK
    "A new imaging modality to non-invasively assess multiple sclerosis pathology".
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30328.
    PubMed     Abstract available


  224. REICH DS
    Imag(in)ing multiple sclerosis: Time to take better pictures.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30307.
    PubMed     Abstract available


  225. ITOH N, Kim R, Peng M, DiFilippo E, et al
    Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30308.
    PubMed     Abstract available


    September 2016
  226. BOIOCCHI C, Monti MC, Osera C, Mallucci G, et al
    Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis.
    J Neuroimmunol. 2016;298:189-93.
    PubMed     Abstract available


  227. TAO Y, Zhang X, Markovic-Plese S
    Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    J Neuroimmunol. 2016;298:181-8.
    PubMed     Abstract available


  228. OZGUN-ACAR O, Celik-Turgut G, Gazioglu I, Kolak U, et al
    Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice.
    J Neuroimmunol. 2016;298:106-16.
    PubMed     Abstract available


  229. COSENTINO M, Zaffaroni M, Legnaro M, Bombelli R, et al
    Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
    J Neuroimmunol. 2016;298:82-9.
    PubMed     Abstract available


  230. MIYAZAKI Y, Niino M, Kanazawa I, Suzuki M, et al
    Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
    J Neuroimmunol. 2016;298:24-31.
    PubMed     Abstract available


  231. EFTHYMIOU G, Dardiotis E, Liaskos C, Marou E, et al
    Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.
    J Neuroimmunol. 2016;298:19-23.
    PubMed     Abstract available


  232. TANAKA M, Tanaka K
    Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;298:16-8.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: